Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Nancy Chang, Ph.D.

Investor and Director at Rgenix

Nancy T. Chang is an investor and Director at Rgenix. Dr. Chang is a renowned biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation, and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug (Xolair) that focused on the allergy-related basis of asthma. In June 2003, the U.S. Food and Drug Administration approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for nearly $1 billion. Dr. Chang grew Tanox from an idea to a substantial publicly traded company pioneering innovative science. Following her success with Tanox, Dr. Chang became an angel investor in healthcare companies and performs philanthropic work in community health-education projects.